tetano
Editor, Senior Moderator
Immun Inflamm Dis
. 2020 Nov 26.
doi: 10.1002/iid3.374. Online ahead of print.
Safety of hydroxychloroquine for treatment or prevention of SARS-CoV-2 infection: A rapid systematic review and meta-analysis of randomized clinical trials
Alberto Enrico Maraolo[SUP] 1 [/SUP], Adriano Grossi[SUP] 2 [/SUP]
Affiliations
Abstract
Introduction: Hydroxycloroquine (HCQ) has been extensively studied for treatment and prevention of coronavirus diseases 2019 (COVID-19) from the start of the pandemic. Conflicting evidence about its usefulness has begun to accrue.
Methods: In the face of controversial results about clinical efficacy of HCQ, we performed a rapid systematic review to assess its safety in the framework of COVID-19 randomized clinical trials.
Results: Five studies investigating 2291 subjects were included. The use of HCQ was associated with higher risk of adverse event compared with placebo or standard of care: odds ratio 4.57, 95% confidence interval 2.14-9.45.
Conclusion: Safety profile of HCQ appears to be unsatisfactory when used to treat or prevent COVID-19, especially in the light of unproved clinical benefit.
Keywords: COVID-19; SARS-CoV-2; hydroxychloroquine; meta-analysis; randomized controlled trials; safety.
. 2020 Nov 26.
doi: 10.1002/iid3.374. Online ahead of print.
Safety of hydroxychloroquine for treatment or prevention of SARS-CoV-2 infection: A rapid systematic review and meta-analysis of randomized clinical trials
Alberto Enrico Maraolo[SUP] 1 [/SUP], Adriano Grossi[SUP] 2 [/SUP]
Affiliations
- PMID: 33244901
- DOI: 10.1002/iid3.374
Abstract
Introduction: Hydroxycloroquine (HCQ) has been extensively studied for treatment and prevention of coronavirus diseases 2019 (COVID-19) from the start of the pandemic. Conflicting evidence about its usefulness has begun to accrue.
Methods: In the face of controversial results about clinical efficacy of HCQ, we performed a rapid systematic review to assess its safety in the framework of COVID-19 randomized clinical trials.
Results: Five studies investigating 2291 subjects were included. The use of HCQ was associated with higher risk of adverse event compared with placebo or standard of care: odds ratio 4.57, 95% confidence interval 2.14-9.45.
Conclusion: Safety profile of HCQ appears to be unsatisfactory when used to treat or prevent COVID-19, especially in the light of unproved clinical benefit.
Keywords: COVID-19; SARS-CoV-2; hydroxychloroquine; meta-analysis; randomized controlled trials; safety.